Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

As the HHS and FDA leadership continues to look for ways to boost transparency and reshape the United States' healthcare ...

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

With a buyout of scPharmaceuticals worth up to $360 million, MannKind is looking to dive into the large and growing field of cardiometabolic treatments. | The company touts a large U.S. market ...

BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. | BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...

Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...

The biopharma industry’s bid to increase drug spending in the U.K. has reached an impasse. | Talks between the U.K.

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...